Tokyo, Japan

Hidenori Harada

This inventor holds 1 USPTO granted patent. Top assignee: Zenyaku Kogyo Kabushiki Kaisha. Active years: 2005.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hidenori Harada. Retrieved from https://idiyas.com/inventor/hidenori-harada-s862vbq6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hidenori Harada: Innovator in Cephem Compounds

Introduction

Hidenori Harada is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cephem compounds. His work has implications for medical diagnostics and treatment.

Latest Patents

Hidenori Harada holds a patent for "Cephem compounds and ESBL-detecting reagents containing the same." This patent describes a cephem compound or pharmaceutically acceptable salt represented by a specific formula. The compound includes various substituents, such as hydrogen atoms, nitro, or cyano groups, and has applications in detecting extended-spectrum beta-lactamases (ESBLs).

Career Highlights

Harada is associated with Zenyaku Kogyo Kabushiki Kaisha, a company known for its focus on pharmaceutical innovations. His work has contributed to advancements in the field, showcasing his expertise and dedication to improving healthcare solutions.

Collaborations

Throughout his career, Hidenori Harada has collaborated with esteemed colleagues, including Keiichi Hiramatsu and Seiichiro Kawashima. These partnerships have fostered a collaborative environment that enhances innovation and research.

Conclusion

Hidenori Harada's contributions to the field of cephem compounds highlight his role as an influential inventor. His patent work and collaborations reflect his commitment to advancing pharmaceutical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…